SOUTH SAN FRANCISCO, CA--(Marketwire - 12/03/09) - Cytokinetics, Incorporated (NASDAQ:CYTK - News) announced today that an abstract summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), is scheduled to be presented as a poster presentation at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS) to be held December 9-13, 2009 at the Henry B. Gonzalez Convention Center, San Antonio, Texas. GSK-923295 is currently being studied in a GlaxoSmithKline sponsored Phase I, first time in humans clinical trial designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate in patients with advanced, refractory solid tumors.
